{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:51:26Z","timestamp":1787017886948,"version":"build-2736575974"},"reference-count":5,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestion"],"published-print":{"date-parts":[[2002]]},"abstract":"<i>Background:<\/i> A definitive treatment for functional dyspepsia (FD), and the role of <i>Helicobacter pylori<\/i> eradication on the course of this disease are controversial. <i>Aim:<\/i> To investigate the effect of a combination of acid-suppressing and prokinetic drugs or eradication therapy on the course of <i>H. pylori<\/i>-positive FD. <i>Method:<\/i> A total of 157 patients with endoscopically-proven <i>H. pylori<\/i>-positive FD and no response to 4 weeks of antacid therapy were randomly divided into 2 groups. 84 were placed on bismuth subnitrate plus metronidazole and amoxicillin (group A) and 73 received ranitidine and metoclopramide for 4 weeks (group B). The severity of symptoms (7 items) were assessed on a 6-point categorical scale. Group B patients who failed to respond to their medication underwent eradication therapy after 3 months. All patients were followed and assessed for 9 months after the end of therapy by the same clinicians who initiated the therapy. <i>Results:<\/i> At the end of the medication period, symptom\u2019s score decreased significantly, and to the same extent. At 3-month follow-up moderate or complete response was achieved in 27.4% (group A) and 19.2% (group B) by intention-to-treat analysis. 34 patients of group B, not responding to treatment, underwent eradication therapy and followed as group A. Eradication of <i>H. pylori<\/i> was successful in 60 of 110 controlled patients (54%). After 9-month follow-up, complete or moderate response was observed in only 30% of 60 patients in whom <i>H. pylori<\/i> had been eradicated (intention-to-treat analysis), compared to 38% in 50 noneradicated cases (p > 0.05, 95% CI: 19\u201343 vs. 24\u201352). <i>Conclusion:<\/i> Eradication therapy with bismuth compound is effective as ranitidine plus metoclopramide in a subgroup of patients with FD not responding to antacid therapy. There is no difference in improvement between patients cured or not cured from <i>H. pylori<\/i> infection. This suggests that bismuth compounds were effective in FD when used in the eradication regimen. Combination therapy with acid-suppressing drugs plus prokinetic and bismuth seems to hold promise for FD.<\/jats:p>","DOI":"10.1159\/000065589","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T17:05:17Z","timestamp":1050426317000},"page":"92-98","source":"Crossref","is-referenced-by-count":14,"title":["Effect of <i>Helicobacter pylori<\/i> Eradication or of Ranitidine plus Metoclopramide on <i>Helicobacter pylori<\/i>-Positive Functional Dyspepsia"],"prefix":"10.1159","volume":"66","author":[{"given":"M.","family":"Alizadeh-Naeeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Saberi-Firoozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pourkhajeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Derakhshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Massarrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2002,11,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812243392601"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812243392602"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910073411502"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.6.759"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7262.659"}],"container-title":["Digestion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/65589","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/65589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:32:01Z","timestamp":1745454721000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000065589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002]]},"references-count":5,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2002,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000065589","archive":["Portico"],"relation":{},"ISSN":["0012-2823","1421-9867"],"issn-type":[{"value":"0012-2823","type":"print"},{"value":"1421-9867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002]]}}}